Novartis Buys The Medicines Company: A $9.7 Billion Gamble on a PCSK9 Cholesterol Drug
Νέο φάρμακο μειώνει τον καρδιαγγειακό κίνδυνο
Τα νέα φάρμακα που θα κυκλοφορήσουν στην Ευρωπαϊκή Ένωση
7 drugs that raised eyebrows in Q3
New AHA/ACC Cholesterol Treatment Guideline Expands Role of LDL Targets
The top 10 drugmakers of 2024
Sanofi and Regeneron's Praluent closes in on sales-boosting CV nod
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look. Agios Pharmaceuticals had a Prescription Drug User Fee Act (PDUFA) action date of Tuesday, August 21, for its ivosidenib (AG-120) for patients with relapsed or refractory (R/R) acute myeloid leukemia … Συνεχίστε να διαβάζετε FDA Action Alert: Mallinckrodt, Kala Pharma, Merck, Eisai and More.
What Did Ian Read Learn From Trump? Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump's thinking on drug pricing and potential policy steps, after talking to the president on the phone and visiting him at the White House in July. You can bet … Συνεχίστε να διαβάζετε Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk.